Episode Details
Back to Episodes
Kymera Therapeutics' Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data
Published 1 year, 3 months ago
Description
He describes the data, which was released on Monday, and highlights the future of the program - including how we will see more data in atopic dermatitis patients by the end of the year. Plus, discussing a new target Kymera recently announced for other immuno-inflammatory diseases, IRF5.